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We are currently in the midst of a revolution in ageing research, with several dietary, genetic and pharmacological interventions now
known to modulate ageing in model organisms. Excitingly, these interventions also appear to have beneficial effects on late-life health.
For example, dietary restriction (DR) has been shown to slow the incidence of age-associated cardiovascular disease, metabolic disease,
cancer and brain ageing in non-human primates and has been shown to improve a range of health indices in humans. While the idea that
DR’s ability to extend lifespan is often thought of as being universal, studies in a range of organisms, including yeast, mice and monkeys,
suggest that this may not actually be the case. The precise reasons underlying these differential effects of DR on lifespan are currently
unclear, but genetic background may be an important factor in how an individual responds to DR. Similarly, recent findings also suggest
that the responsiveness of mice to specific genetic or pharmacological interventions that modulate ageing may again be influenced by
genetic background. Consequently, while there is a clear driver to develop interventions to improve late-life health and vitality, under-
standing precisely how these act in response to particular genotypes is critical if we are to translate these findings to humans. We will
consider of the role of genetic background in the efficacy of various lifespan interventions and discuss potential routes of utilising genetic
heterogeneity to further understand how particular interventions modulate lifespan and healthspan.
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The ageing process is characterised by progressive loss in
cellular homeostasis and a decline in physiological function
(Balcombe and Sinclair, 2001), resulting in an overall decline
in fecundity and increased risk of mortality over time. While
ageing was historically believed to be an inevitable and
intractable process (for discussion see (Kirkwood and
Holliday, 1979; Kirkwood, 2005, 2008; Munch et al.,
2008)), we now know that ageing can be modulated throughAbbreviations: AL, Ad libitum; DR, dietary restriction; IIS, insulin/insulin
like growth factor-1 signalling; RI, recombinant inbred; TOR, target of
rapamycin.
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terventions such as dietary restriction (DR) (Kenyon, 2005;
Mair and Dillin, 2008; Rikke et al., 2010; Swindell, 2012;
Gems and Partridge, 2013). DR is defined as the reduction
in overall energy intake, or in specific components of the diet,
relative to that consumed normally by individuals with free
ad libitum (AL) access to food. DR has been conclusively
shown to extend lifespan in a wide range of taxonomically
diverse organisms (Mair and Dillin, 2008; Selman, 2014). In
addition, studies have demonstrated that particular genetic
pathways modulate ageing through the observation that dele-
tion of single key genes can extend lifespan and healthspan in
model organisms. In particular, reduced signalling via the in-
sulin/insulin like growth factor-1 (IGF1) signalling (IIS)
pathway or the target of rapamycin (TOR) pathway shows
highly conserved effects on lifespan across wide evolutionaryntal Biology, Chinese Academy of Sciences, and Genetics Society of China.
r the CC BY license (http://creativecommons.org/licenses/by/3.0/).
498 L. Mulvey et al. / Journal of Genetics and Genomics 41 (2014) 497e503distances (Kenyon, 2005; Piper et al., 2008; Broughton and
Partridge, 2009; Kenyon, 2010; Selman and Withers, 2011).
Indeed, differential expression of several IIS and TOR genes is
associated with longevity in humans (Deelen et al., 2013;
Passtoors et al., 2013). More recently pharmacological in-
terventions, including rapamycin and metformin, have been
shown to extend lifespan in model organisms. This has led to
renewed hope in identifying realistic, efficacious and safe
pharmacological interventions that will increase the period of
our life free from age-related diseases (Selman, 2014).
Excitingly, evidence exists that some molecular processes
affected by these different interventions may overlap, thereby
suggesting some level of commonality (Selman et al., 2009;
Yan et al., 2012), although other studies suggest that specific
interventions may function through distinct mechanisms
(Masternak et al., 2004; Bhattacharya et al., 2012; Fok et al.,
2014). Furthermore, recent research has suggested that the
effectiveness of each intervention on ageing is highly sensitive
to the effects of genetic background. Therefore, the use of
such interventions in genetically diverse human beings be-
comes questionable unless we fully understand the precise role
that genetic background plays. In this review, we will discuss
the evidence that genetic background plays a role in lifespan
extension in response to dietary, genetic and pharmacological
interventions in mice.
GENETIC BACKGROUND AND DIETARY
RESTRICTION (DR)
The first studies on lifespan extension in animals in response
to DR were published almost 100 years ago (Osborne et al.,
1917; McCay et al., 1935). Consequently, DR is the most
reproducible and widely used intervention to modulate life-
span (Masoro, 1995; Speakman and Mitchell, 2011; Selman,
2014). In addition, DR has been shown to induce significant
health benefits, with mouse studies showing DR protects ani-
mals against a range of age-related and non-age-related pa-
thologies, including various cancers, glaucoma, glucose
intolerance and sarcopaenia (Weindruch and Walford, 1982;
Sheldon et al., 1995a, 1995b; McKiernan et al., 2004;
Hempenstall et al., 2010). Furthermore, DR decreases patho-
genesis and increases survival in a range of mouse models of
disease including Parkinson’s disease (Duan and Mattson,
1999), Alzheimer’s disease (Halagappa et al., 2007), viral
myocarditis (Kanda et al., 2007) and pancreatic cancer
(Lanza-Jacoby et al., 2013). The positive effects of DR on
health also extend to Rhesus monkeys, where it has been
shown that the incidence of cancer, cardiovascular disease,
type-II diabetes mellitus and brain atrophy with advancing age
are reduced relative to AL controls (Colman et al., 2009, 2014;
Mattison et al., 2012). Similarly, DR has been shown to induce
significant beneficial effects on metabolism (Weiss et al.,
2006) and cardiac function (Stein et al., 2012) in humans,
and lowers several risk factors associated with coronary heart
disease (Fontana et al., 2007). Despite the large number of
studies that have used DR to extend lifespan we still do not
understand the precise mechanism(s) through which DR actsto modulate lifespan. In addition, studies using an increasing
number of different model systems have implicated that the
effects of DR on lifespan extension are not universal and
question whether DR is indeed a public modulator of
longevity.
Several studies in organisms ranging from yeast to non-
human primates have reported no effect of DR on lifespan
(Harrison and Archer, 1987; Kirk, 2001; Carey et al., 2002;
Forster et al., 2003; Liao et al., 2010; Rikke et al., 2010;
Mattison et al., 2012; Schleit et al., 2013). Another caveat
has recently emerged from research on mice which indicates
that specific genotypes can affect the extent and direction of
the lifespan response to DR. As an example, the effect of DR
on lifespan in DBA/2 mice has ranged from lifespan extension
to lifespan shortening (Fernandes et al., 1976; Turturro et al.,
1999; Forster et al., 2003). Clear differences in key variables
including terms of husbandry conditions, extent of restriction,
diet, gender and age of DR initiation will undoubtedly vary
across different studies which may help explain the differences
in the findings reported. However, it is also well established
that DBA/2 mice show distinct differences in a range of
metabolic parameters (e.g., insulin sensitivity, glucose toler-
ance, metabolic rate) under both AL and DR feeding when
compared to strains such as C57BL/6 mice (Funkat et al.,
2004; Goren et al., 2004; Berglund et al., 2008; Hempenstall
et al., 2010), which may underlie their overall responsive-
ness to DR. It is also clear that extended lifespan, when
observed, in DBA/2 mice in response to DR is more moderate
than the extension reported in C57BL/6 mice (Turturro et al.,
1999). Recently, lifespan was assayed in heterogeneous ILS-
XISS recombinant inbred (RI) mice derived from eight distinct
mouse strains (Liao et al., 2010; Rikke et al., 2010). In two
separate studies undertaken by the Universities of Texas and
Colorado, clear lifespan differences existed between distinct
ILSXISS lines under 40% DR. The earlier study examined 39
female lines and 41 male lines under DR and reported that
only 21% of female and 5% of male lines showed a significant
lifespan extension under DR (Liao et al., 2010). In this study, a
higher number of lines (26% and 27% for males and females,
respectively) showed a significant shortening of lifespan under
DR. Similarly, the second study examined 42 female lines
again and reported a significant difference in terms of the
response to DR across different lines, with 21% of females
showing lifespan extension and 19% showing significant
truncation of lifespan under DR (Rikke et al., 2010). Similarly,
the differential effect of DR on lifespan reported in Rhesus
monkeys by the Wisconsin National Primate Centre (Colman
et al., 2009, 2014) and the National Institute of Aging
(Mattison et al., 2012) may be partly explained by inter-study
differences in geographical origin and genetic background of
the experimental animals (Mattison et al., 2012; Partridge,
2012; Colman et al., 2014; Selman, 2014). Currently, we do
not understand how genetic background may impact on how
DR acts to extend life. In ILSXISS mice at least it may be that
the optimal DR regime differs between lines and consequently
the 40% DR regime employed (Liao et al., 2010; Rikke et al.,
2010) was too extreme to maximise lifespan in all lines
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if specific lines are more prone to particular pathologies under
both AL and DR conditions. However, comparative-type ap-
proaches by taking advantage of the differential responses to
DR across different mouse strains or RI lines may be a
powerful approach to understand precisely how DR acts to
slow ageing (Selman, 2014). Consequently, a larger subset of
more genetically diverse rodent models should be studied
under DR, along with the greater use of non-model organisms
to increase our understanding of how DR acts.
GENETIC BACKGROUND AND MUTANT MICE
Significant research efforts over the last couple of decades,
initially using invertebrate model organisms, have demon-
strated that decreased IIS and TOR signalling extends lifespan
in a highly conserved fashion across model organisms
(Kenyon, 2005; Piper et al., 2008; Gems and Partridge, 2013).
In addition, in mice a large number of studies have also shown
that specific disruptions in somatotrophic function also ex-
tends lifespan significantly relative to wild type controls
(Bartke, 2011). Furthermore, it is evident that long-lived
genetically mutant mice tend to display a much greater pro-
portion of their life free from age-related pathologies (Selman
and Withers, 2011).
As genetic interventions modulating lifespan is a more
recent finding compared to studies on DR, it is unsurprising
that few studies, so far, have investigated how genetic back-
ground can impact on the life-extending effects of specific
mutations. The most widely used genetically modified mice in
ageing research are those which harbour mutations that result
in growth hormone (GH) deficiency or GH resistance (for
review see Bartke, 2011; Bartke et al., 2013); Ames mice
(Prop1df), Snell mice (Pit1dw) including growth hormone re-
ceptor knockout (GHRKO) and the ‘little’ mouse
(GHRHRlit). In addition to altered somatotrophic function,
these animals appear to have secondary suppression of IIS
(Bartke, 2011; Bartke et al., 2013). These models show
reproducible lifespan extension across different studies and
appear to be protected against a range of age-related pathol-
ogies (Brown-Borg et al., 1996; Flurkey et al., 2001; Kinney
et al., 2001; Flurkey et al., 2002; Coschigano et al., 2003;
Ikeno et al., 2003). The impact of genetic background on
lifespan has been studied in Snell mice, where it has been
shown that the lifespan extension in these animals is consis-
tent across different genetic backgrounds (Flurkey et al.,
2001; Flurkey et al., 2002). However, it should be noted
that the additive effects on lifespan with DR reported on a
mixed genetic background (Bartke et al., 2001) were lost with
a greater penetrance of the C57BL/6J background (Garcia
et al., 2008). In addition, Ames mice backcrossed on to a
C57BL/6 or 129S1/SvlmJ background led to a significant
increase in perinatal mortality (Nasonkin et al., 2004). In
2003, two separate studies were the first to demonstrate that
reduced IIS extended lifespan was also conserved in mam-
mals. These studies reported that the loss of the insulin re-
ceptor specifically in white adipose tissue (Bluher et al.,2003) or haploinsufficiency in the gene encoding the insulin
like growth factor 1-receptor (Igf1r/þ) (Holzenberger et al.,
2003) were sufficient to increase lifespan in mice.
Holzenberger et al. (2003) showed that female Igf1r/þ mice
maintained on the 129Sv background were 33% longer lived
than wild type mice, although the effect in male Igf1r/þ mice
was non-significant (16%). In addition, they showed that fe-
male but not male mice were resistant to the effects of the
oxidant stressor paraquat. This study has since been criticised
due to the short lifespan of the control animals and the small
sample size used (Liang et al., 2003). More recently, a second
study was undertaken to examine lifespan in Igf1r/þ mice.
Lifespan and end-of-life pathology were examined under
housing conditions optimised to maximise the lifespan of the
control mice (Bokov et al., 2011). In addition, the Igf1r/þ
mice were re-derived on the C57BL/6 background for at least
10 generations before lifespan was assayed. This second study
reported a more modest increase in female lifespan (w5%;
significant using the log-rank test) relative to controls and a
slight, but non-significant, reduction in male lifespan. While
genetic background and the targeting event used may help
explain some of the differences reported between the two
studies, the authors in the second study (Bokov et al., 2011)
tend to discount this as significant overlap in terms of the
metabolic and oxidative stress resistant phenotype which was
seen between each study. Interestingly, Bokov et al. (2011)
also examined lifespan in Igf1r/þ female mice on a F1
hybrid C57BL/6  129Sv background and showed no effect
of haploinsufficiency on lifespan. Consequently, the authors
of the second study (Bokov et al., 2011) proposed that sub-
optimal housing conditions may have led to increased stress
exposure of all mice in the earlier study (Holzenberger et al.,
2003). This was hypothesized to lead to a survival advantage
of the stress resistant Igf1r/þ females over wild type females,
which was not enjoyed by Igf1r/þ males.
GENETIC BACKGROUND AND
PHARMACOLOGICAL INTERVENTIONS
While evidence suggests DR may not have the ubiquitous
effect on lifespan as originally proposed, animals under DR
tend to retain a longer period of life free from ill health,
including the onset and impact of age-related pathologies such
as type-2 diabetes, cardiovascular disease and cancer. Conse-
quently, much current research aims to identify drugs which
mimic the effects of DR, i.e., extend vitality in old age.
Several compounds have been identified, including rapamycin,
metformin and resveratrol, which appear to have significant
potential in the development of efficacious and safe DR mi-
metics (Selman, 2014). However, the precise mechanism
through which these interventions act is still unclear and
research from murine studies has demonstrated that genotype
appears to be important in how particular DR mimetics impact
on an individual’s phenotype.
The TOR pathway appears to be a highly conserved life-
span determinant (Kapahi et al., 2004; Selman et al., 2009;
Kapahi et al., 2010; Lamming et al., 2012; Wu et al., 2013),
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Partridge, 2011) by responding to a range of stimuli including
various growth factors, nutrients and energy status (Fig. 1).
TOR kinase, the central component of the TOR pathway,
forms two functionally different complexes: TOR complex 1
(TORC1), which plays a central role in regulating cellular
processes associated with growth and differentiation, and
TORC2 which has a regulatory role in the insulin signalling
cascade (Lamming and Sabatini, 2011; Lamming et al., 2012,
2013; Selman and Partridge, 2012). Rapamycin, a macrolide
compound, has been shown to be a highly potent inhibitor of
mTORC1, and more recently also of mTORC2 (Lamming and
Sabatini, 2011; Lamming et al., 2012, 2013a, 2013b; Selman
and Partridge, 2012). In model organisms, rapamycin treat-
ment has been shown to extend lifespan (Harrison et al., 2009;
Anisimov et al., 2010b; Bjedov et al., 2010; Anisimov et al.,
2011b; Miller et al., 2011; Neff et al., 2013) and in mice
can attenuate some, but not all, ageing-related phenotypes
(Wilkinson et al., 2012; Neff et al., 2013). However, mouse
studies using rapamycin to modulate lifespan have shown that
its effects on metabolism appear to be highly sensitive to ge-
netic background. As an example, rapamycin treatment in-
duces overt insulin resistance in C57BL/6 mice (Lamming
et al., 2012) but insulin resistance was not reported in young
or old HET3 mice (Lamming et al., 2013a). In addition,
rapamycin appears to have temporal effects on metabolism inAgeing
Growth factors Nutrients Stress
mTOR
mRNA translation  Ribosome biogen
proliferation
Cell growth Autophagy
Fig. 1. Overview of mammalian target of rapamycin (mTOR) regulated processesmice, leading to hyperinsulinaemia, insulin resistance and
glucose tolerance after 2 weeks of rapamycin treatment but
hypoinsulinaemia and insulin sensitivity after 20 weeks of
treatment (Fang et al., 2013). Recent findings have shown that
rapamycin induces sex-dependent effects on lifespan (Miller
et al., 2014) and that there appears to be less overlap with
DR, in terms of metabolism and transcription, than was
originally believed (Fok et al., 2014; Miller et al., 2014).
Similarly, the effect of the biguanide metformin on lifespan
and health in mice appears to be, at least partly, dependent on
genotype, but also dependent on sex and age at which met-
formin treatment is initiated (Anisimov et al., 2005, 2008,
2010a, 2011a).
CONCLUDING REMARKS
It is clear that the dramatic rise in the proportion of elderly
individuals making up our population is going to have sig-
nificant ramifications. Ageing is associated with a decrease in
the quality of life linked to an increase in the risk of devel-
oping a range of pathologies, including various dementias,
type-2 diabetes, osteoporosis, many cancers and cardiovas-
cular disease. Consequently understanding the fundamental
processes that drive ageing and increase the susceptibility to
develop disease is undoubtedly one of the greatest current
challenges in biomedical research. To add to this challenge, itDietary restricition
Rapamycin
 Transcriptionesis
Genotype
.
501L. Mulvey et al. / Journal of Genetics and Genomics 41 (2014) 497e503is becoming increasingly prevalent in the literature that ge-
netic heterogeneity is likely to play a critical role in the
response to interventions which modulate lifespan and
healthspan. Another potential confounding issue is the
focussed use of model organisms in such studies, for example,
the small number of mouse strains used in ageing research has
been highlighted as a potential limitation to the identification
of longevity-associated genes (Yuan et al., 2013). Future
research efforts should perhaps complement model organism
studies with those examining ageing in non-model organisms
(Selman et al., 2012), for example, employing comparative-
type approaches to study ageing in fast-ageing and slow-
ageing species (Austad, 2010a, 2010b). Additionally, we
should also take greater advantage of the inherent differences
in longevity and pathology at death seen across different
mouse strains (Storer, 1966) to further understand how spe-
cific interventions, including DR, genetic inactivation of IIS/
mTOR and rapamycin treatment, act to modulate lifespan and
health in the background of increasing genetic heterogeneity.ACKNOWLEDGEMENTS
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